



Toxicological Profile for 3,3'-Dichlorobenzidine

June 2022



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

CS274127-A

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute, intermediate, and chronic exposures;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Patrick N. Breyse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention



Christopher M. Reh, Ph.D.
Associate Director
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

VERSION HISTORY

Date	Description
June 2022	Final toxicological profile released
July 2021	Draft for public comment toxicological profile released
May 2020	Addendum to the toxicological profile released
December 1998	Final toxicological profile released
October 1989	Final toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Custodio Muianga, M.P.H., Ph.D. (Lead)
G. Daniel Todd, Ph.D.

ATSDR, Office of Innovation and Analytics,
Toxicology Section, Atlanta, GA

Adriana Antezana, M.P.H.
Kerry Diskin, DSc.
Meghan Lynch, DSc.
Abt Associates, Cambridge, MA

Julie M. Klotzbach, Ph.D.
Ramsey Hanna, Ph.D.
SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Office of Community Health and Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice; EPA.

PEER REVIEWERS

1. James V. Bruckner, PhD; Professor Department of Pharmaceutical and Biomedical Sciences; University of Georgia; Athens, Georgia
2. Kenneth Rosenman, MD, FACE, FACOEM, FACPM; Professor of Medicine, Chief, Division of Occupational and Environmental Medicine; Michigan State University; East Lansing, Michigan
3. Harold S. Freeman, PhD, Professor of Polymer and Color Chemistry, Wilson College of Textiles; North Carolina State University; Raleigh, North Carolina

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

DISCLAIMER	ii
FOREWORD	iii
VERSION HISTORY	v
CONTRIBUTORS & REVIEWERS	vi
CONTENTS	vii
LIST OF FIGURES	ix
LIST OF TABLES	x
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH	1
1.1 OVERVIEW AND U.S. EXPOSURES	1
1.2 SUMMARY OF HEALTH EFFECTS	2
1.3 MINIMAL RISK LEVELS (MRLs)	3
CHAPTER 2. HEALTH EFFECTS	6
2.1 INTRODUCTION	6
2.2 DEATH	18
2.3 BODY WEIGHT	18
2.4 RESPIRATORY	18
2.5 CARDIOVASCULAR	19
2.6 GASTROINTESTINAL	19
2.7 HEMATOLOGICAL	19
2.8 MUSCULOSKELETAL	20
2.9 HEPATIC	20
2.10 RENAL	20
2.11 DERMAL	20
2.12 OCULAR	21
2.13 ENDOCRINE	21
2.14 IMMUNOLOGICAL	22
2.15 NEUROLOGICAL	22
2.16 REPRODUCTIVE	22
2.17 DEVELOPMENTAL	22
2.18 OTHER NONCANCER	22
2.19 CANCER	22
2.20 GENOTOXICITY	25
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS	29
3.1 TOXICOKINETICS	29
3.1.1 Absorption	29
3.1.2 Distribution	30
3.1.3 Metabolism	31
3.1.4 Excretion	36
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	38
3.1.6 Animal-to-Human Extrapolations	38
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	38
3.3 BIOMARKERS OF EXPOSURE AND EFFECT	41
3.3.1 Biomarkers of Exposure	42

3.3.2	Biomarkers of Effect	42
3.4	INTERACTIONS WITH OTHER CHEMICALS	44
CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION		45
4.1	CHEMICAL IDENTITY	45
4.2	PHYSICAL AND CHEMICAL PROPERTIES	45
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE		49
5.1	OVERVIEW	49
5.2	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	50
5.2.1	Production	50
5.2.2	Import/Export.....	51
5.2.3	Use	51
5.2.4	Disposal.....	51
5.3	RELEASES TO THE ENVIRONMENT.....	52
5.3.1	Air	52
5.3.2	Water.....	52
5.3.3	Soil	53
5.4	ENVIRONMENTAL FATE	53
5.4.1	Transport and Partitioning.....	53
5.4.2	Transformation and Degradation	56
5.5	LEVELS IN THE ENVIRONMENT.....	59
5.5.1	Air	61
5.5.2	Water.....	61
5.5.3	Sediment and Soil	62
5.5.4	Other Media	63
5.6	GENERAL POPULATION EXPOSURE.....	64
5.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	66
CHAPTER 6. ADEQUACY OF THE DATABASE.....		67
6.1	INFORMATION ON HEALTH EFFECTS.....	67
6.2	IDENTIFICATION OF DATA NEEDS	69
6.3	ONGOING STUDIES.....	77
CHAPTER 7. REGULATIONS AND GUIDELINES		78
CHAPTER 8. REFERENCES		80
APPENDICES		
APPENDIX A.	ATSDR MINIMAL RISK LEVEL WORKSHEETS	A-1
APPENDIX B.	LITERATURE SEARCH FRAMEWORK FOR 3,3'-DICHLOROBENZIDINE	B-1
APPENDIX C.	USER'S GUIDE	C-1
APPENDIX D.	QUICK REFERENCE FOR HEALTH CARE PROVIDERS	D-1
APPENDIX E.	GLOSSARY	E-1
APPENDIX F.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS	F-1

LIST OF FIGURES

1-1. Health Effects Found in Animals Following Oral Exposure to 3,3'-Dichlorobenzidine	2
1-2. Summary of Sensitive Targets of 3,3'-Dichlorobenzidine – Oral.....	4
2-1. Overview of the Number of Studies Examining 3,3'-Dichlorobenzidine Health Effects	8
2-2. Levels of Significant Exposure to 3,3'-Dichlorobenzidine – Oral.....	15
3-1. Chemical Structures of 3,3'-Dichlorobenzidine Metabolites	33
3-2. Potential Form of the Nitroso Intermediate	33
3-3. Hydroxy- Metabolites of 3,3'-Dichlorobenzidine.....	33
5-1. Number of NPL Sites with 3,3'-Dichlorobenzidine Contamination	49
6-1. Summary of Existing Health Effects Studies on 3,3'-Dichlorobenzidine By Route and Endpoint	68

LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for 3,3'-Dichlorobenzidine	5
2-1. Health Effects in Humans Exposed to 3,3'-Dichlorobenzidine	9
2-2. Levels of Significant Exposure to 3,3'-Dichlorobenzidine – Oral.....	12
2-3. Genotoxicity of 3,3'-Dichlorobenzidine <i>In Vitro</i>	26
2-4. Genotoxicity of 3,3'-Dichlorobenzidine <i>In Vivo</i>	27
4-1. Chemical Identity of 3,3'-Dichlorobenzidine (and its Salts), 3,3'-Dichlorobenzidine Dihydrochloride, 3,3'-Dichlorobenzidine Dihydrogen Bis(sulphate), and 3,3'-Dichlorobenzidine Sulphate	46
4-2. Physical and Chemical Properties of 3,3'-Dichlorobenzidine (and its Salts), 3,3'-Dichlorobenzidine Dihydrochloride, 3,3'-Dichlorobenzidine Dihydrogen Bis(sulphate), and 3,3'-Dichlorobenzidine Dihydrogen Bis(sulphate).....	47
5-1. Lowest Limit of Detection for 3,3'-Dichlorobenzidine Based on Standards	60
5-2. Summary of Environmental Levels of 3,3'-Dichlorobenzidine in the United States.....	60
5-3. 3,3'-Dichlorobenzidine Levels in Water, Soil, and Air of National Priorities List (NPL) Sites.....	61
7-1. Regulations and Guidelines Applicable to 3,3'-Dichlorobenzidine.....	78